A detailed history of Ubs Group Ag transactions in Hcw Biologics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 4,285 shares of HCWB stock, worth $2,313. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,285
Previous 605 608.26%
Holding current value
$2,313
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.64 - $1.68 $2,355 - $6,182
3,680 Added 608.26%
4,285 $2,000
Q1 2024

May 13, 2024

SELL
$1.1 - $1.77 $33 - $53
-30 Reduced 4.72%
605 $1,000
Q4 2023

Feb 09, 2024

BUY
$0.92 - $2.14 $389 - $905
423 Added 199.53%
635 $0
Q3 2023

Nov 09, 2023

BUY
$1.75 - $2.31 $371 - $489
212 New
212 $0
Q1 2023

May 12, 2023

SELL
$1.12 - $2.19 $408 - $799
-365 Reduced 95.8%
16 $0
Q4 2022

Feb 08, 2023

BUY
$1.84 - $2.36 $701 - $899
381 New
381 $0
Q2 2022

Aug 10, 2022

BUY
$1.96 - $3.17 $687 - $1,112
351 Added 20.59%
2,056 $5,000
Q1 2022

May 16, 2022

BUY
$1.9 - $2.73 $3,239 - $4,654
1,705 New
1,705 $5,000
Q4 2021

Feb 14, 2022

SELL
$2.32 - $4.73 $86,730 - $176,826
-37,384 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$3.14 - $6.3 $117,385 - $235,519
37,384 New
37,384 $119,000

Others Institutions Holding HCWB

About HCW Biologics Inc.


  • Ticker HCWB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,833,100
  • Market Cap $19.3M
  • Description
  • HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...
More about HCWB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.